made to offer the patient a minimally invasive tricuspid valve replacement by a transcatheter procedure. The risks of a transcatheter procedure were discussed with her, and she provided written informed consent.
The option of a transatrial approach was considered, but this would still have required a thoracotomy, and with the introduction of the new 19F Edwards-SAPIEN XT valve (Edwards Lifesciences, Irvine, CA), transjugular access was preferred. Because the old prosthesis was a size 31, there was concern that the 26-mm Edwards valve would not fit securely. Transesophageal echocardiography showed extensive calcification of the prosthesis, which was viewed as adequate to anchor the Edwards prosthesis. We furthermore decided to overexpand the prosthesis to 27 mm, because the anticipated central regurgitation of the valve resulting from the overexpansion was likely to be mild and well tolerated.
The patient was admitted for intravenous heparinization, and her oral warfarin was stopped. The procedure was performed in the catheterization laboratory with the patient under light general anesthesia to enable constant transesoph- Figure 1 . The continuous wave spectral Doppler of the degenerate tricuspid prosthesis before the procedure showing a profile of severe tricuspid stenosis with averaged (because of atrial fibrillation) peak and mean gradients of 12 and 9, respectively. Vmax indicates maximum flow velocity; Vmean, mean flow velocity; Pmax, maximal pressure gradient: Pmean, mean pressure gradient; Env Ti, duration of measured envelope; VTI, velocity time integral; HR, heart rate. (Figure 3) , and downward pushing force resulted in prolapse of the device down toward the inferior vena cava. At this point, a final decision was made to use a transfemoral Edwards SAPIEN XT device rather than the transapical one, with its much shorter delivery system, because the transfemoral Novoflex delivery system has a tip that can be deflected to aid in aiming the device in the direction of the tricuspid valve. The patient was extubated on the table and mobilized on day 1. She lost 10 kg in weight in the next 4 days and reported immediate improvement in dyspnea symptoms. Postprocedural transthoracic echocardiography showed that the device was well anchored, with no paravalvular leaks. The mean gradient across the valve was 3 mm Hg. Oral anticoagulation was reestablished before discharge.
At 2 months after the procedure, the patient is still in New York Heart Association class 1 functional class despite cessation of diuretic treatment.
Discussion
With the advent of transcatheter aortic valve implantation, a new treatment option has become available for patients with inoperable aortic valve stenosis. The calcified degenerated native aortic valve has a rough inner surface that acts as an effective anchor for the prosthesis. The irregular inner surface and metal frame of a degenerated bioprosthesis have similar characteristics, and form an ideal docking station for a transcatheter valve. This has led to a number of valve-invalve implants, mostly in the aortic position. 1 The first case of transcatheter valve-in-valve tricuspid valve replacement was described by Hon et al. 2 Their approach was, however, via a thoracotomy and direct puncture of the right atrium. This has definite advantages with regard to delivery of the device, but remains more invasive. The first transcatheter tricuspid valvein-valve procedure was performed by Leen van Garsse, but differed from the case described here in a number of ways:
The patient described by van Garse was not a surgical candidate, she was placed on extracorporeal circulation for the duration of the procedure, the valve was deployed under rapid ventricular pacing, and the older 24F Edwards SAPIEN device was used. 3 Using the new Edwards SAPIEN XT device required mounting it on the balloon shaft in an orientation opposite to its design. When the balloon is pulled back into the device after exiting the distal end of the delivery sheath, it has the potential to cause folding or damage to the valve cusps. We did not encounter this, and believe that this theoretical risk is well justified by the smaller caliber of the delivery sheath.
Other potential pitfalls we considered included stability of the device within the tricuspid prosthesis; the degenerate bioprosthesis tends to have less bulky calcification than a senile aortic stenosis valve, but the wire frame of the valve adds to the potential of the valve to grip the transcatheter valve, and the low pressure system of the right heart will place less strain on the new prosthesis. Undersizing of our transcatheter valve was a concern, and in the future, one could consider larger valves when they become available. Size of the access vessel was a consideration, but because of the severely congested venous system, this concern was unfounded. Crossing of the degenerated tricuspid prosthesis was difficult because of its angle and downward prolapsing of the device when pressure was applied. A femoral approach may prove easier, because the route may be straighter with better transmission of pushing forces.
This patient presented with a rare combination of problems, and it is unlikely that this procedure would become widely used. If indicated, however, it is feasible provided that a large enough device is available and the approach is evaluated carefully. Rapid ventricular pacing and extracorporeal circulatory support are not mandatory. 
